JP7078538B2 - がんの治療のためのカンナビジオール及び第二の治療剤を含む組成物 - Google Patents

がんの治療のためのカンナビジオール及び第二の治療剤を含む組成物 Download PDF

Info

Publication number
JP7078538B2
JP7078538B2 JP2018541599A JP2018541599A JP7078538B2 JP 7078538 B2 JP7078538 B2 JP 7078538B2 JP 2018541599 A JP2018541599 A JP 2018541599A JP 2018541599 A JP2018541599 A JP 2018541599A JP 7078538 B2 JP7078538 B2 JP 7078538B2
Authority
JP
Japan
Prior art keywords
cancer
cheh
aebs
cbd
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018541599A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018536706A5 (enExample
JP2018536706A (ja
Inventor
ネイサン、イラーナ
ナラサイア ウパラパティ、ラクシュミ
フォーゲル、ツヴィ
ジャナット ゲラルニック、アデラ
Original Assignee
ジェイ ファーマ、インコーポレイティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェイ ファーマ、インコーポレイティッド filed Critical ジェイ ファーマ、インコーポレイティッド
Publication of JP2018536706A publication Critical patent/JP2018536706A/ja
Publication of JP2018536706A5 publication Critical patent/JP2018536706A5/ja
Application granted granted Critical
Publication of JP7078538B2 publication Critical patent/JP7078538B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018541599A 2015-10-27 2016-10-27 がんの治療のためのカンナビジオール及び第二の治療剤を含む組成物 Active JP7078538B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562246780P 2015-10-27 2015-10-27
US62/246,780 2015-10-27
PCT/IL2016/051166 WO2017072773A1 (en) 2015-10-27 2016-10-27 Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2018536706A JP2018536706A (ja) 2018-12-13
JP2018536706A5 JP2018536706A5 (enExample) 2019-12-05
JP7078538B2 true JP7078538B2 (ja) 2022-05-31

Family

ID=57406292

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018541599A Active JP7078538B2 (ja) 2015-10-27 2016-10-27 がんの治療のためのカンナビジオール及び第二の治療剤を含む組成物

Country Status (10)

Country Link
US (1) US11090275B2 (enExample)
EP (1) EP3368024B1 (enExample)
JP (1) JP7078538B2 (enExample)
KR (1) KR20180102053A (enExample)
CN (1) CN109310648B (enExample)
AU (1) AU2016347662B2 (enExample)
BR (1) BR112018008601A2 (enExample)
CA (2) CA3002767C (enExample)
IL (1) IL258854B2 (enExample)
WO (1) WO2017072773A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020161083A1 (en) * 2019-02-04 2020-08-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating blood-brain barrier
EP3993780A4 (en) * 2019-07-02 2023-07-26 Portland Technology Holdings LLC HEMP EXTRACT FOR THE TREATMENT OF PAIN, CANCER AND EPILEPSY IN ANIMALS
CA3109520C (en) * 2019-07-21 2021-09-07 Scf Pharma Inc. Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof
EP4132486A4 (en) * 2020-04-09 2024-04-03 Laviolette, Steven Robert Combination of cannabidiol and a ppar agonist
CN111773390B (zh) * 2020-07-01 2021-08-20 南京大学 一种药物在制备治疗脑转移瘤及其相关疾病的药品中的应用
CN113368085A (zh) * 2021-06-05 2021-09-10 昆明医科大学第一附属医院 大麻二酚在调节肿瘤微生态治疗乳腺癌药物研制中的应用
CN113384563A (zh) * 2021-06-16 2021-09-14 冯敏 大麻二酚在制备治疗非霍奇金淋巴瘤的药物中的应用
KR20240116463A (ko) 2021-10-26 2024-07-29 더 유니버시티 오브 뉴캐슬 대마 추출물을 이용한 자궁내막증 및 기타 비암성 부인과 장애의 치료 방법
WO2023076931A2 (en) 2021-10-26 2023-05-04 Ecofibre Limited Systems and methods for producing hemp extracts and compositions
IL312273A (en) 2021-10-26 2024-06-01 Ecofibre Usa Inc Methods for treating endometrial cancer using hemp extract
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods
WO2024003373A1 (en) * 2022-06-30 2024-01-04 Univerza V Mariboru Cannabinoid compositions against cancer, their identification and personalization of cannabis-based cancer therapy
US20240009211A1 (en) * 2022-07-05 2024-01-11 Neocannbio Co., Ltd. Pharmaceutical composition for treatment of lung cancer comprising cannabidiol and anticancer agent as active ingredients, and use thereof
KR20240036953A (ko) * 2022-09-14 2024-03-21 주식회사 네오켄바이오 칸나비디올 및 항암제를 유효성분으로 포함하는 간암 치료용 약학 조성물 및 이의 용도
WO2024091987A1 (en) 2022-10-26 2024-05-02 Ecofibre USA Inc. Methods of treating estrogen sensitive diseases with cannabis extract
WO2024091989A1 (en) 2022-10-26 2024-05-02 Ecofibre USA Inc. Stabilized compositions comprising cannabidiol
WO2024097631A2 (en) * 2022-11-02 2024-05-10 Morehouse School Of Medicine Methods of treating pain and drepression

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011522028A (ja) 2008-06-04 2011-07-28 ジーダブリュー・ファーマ・リミテッド 非カンナビノイド化学療法剤（例えばｓｅｒｍ又はアルキル化剤）と組合せたカンナビノイド
JP2014530247A (ja) 2011-10-18 2014-11-17 ジーダブリュー・ファーマ・リミテッドＧｗ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ 乳がんの治療に使用されるフィトカンナビノイド

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
AU664978B2 (en) * 1990-12-17 1995-12-14 University Of Manitoba Improved treatment method for cancer
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6380253B1 (en) * 2000-01-05 2002-04-30 Efa Sciences Llc Method of stabilizing and potentiating the action of anti-angiogenic substances
US20020040011A1 (en) * 2000-06-01 2002-04-04 Brown Dennis M. Naphthoquinone compositions and uses thereof
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
US9084771B2 (en) * 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2471987B (en) * 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
FR2947340B1 (fr) * 2009-06-25 2011-08-12 Affichem Detection de l'etat oncogene de cellules humaines ou de mammiferes par presence d'un marqueur et evaluation de l'activite d'un medicament par dosage dudit marqueur
GB2515312A (en) 2013-06-19 2014-12-24 Gw Pharma Ltd The use of phytocannabinoids in the treatment of ovarian carcinoma
GB2527590A (en) * 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011522028A (ja) 2008-06-04 2011-07-28 ジーダブリュー・ファーマ・リミテッド 非カンナビノイド化学療法剤（例えばｓｅｒｍ又はアルキル化剤）と組合せたカンナビノイド
JP2014530247A (ja) 2011-10-18 2014-11-17 ジーダブリュー・ファーマ・リミテッドＧｗ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ 乳がんの治療に使用されるフィトカンナビノイド

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Current Opinion in Pharmacology，2012, Vol.12, No.6，pp.696-703
Molecular Cancer Therapeutics，2011, Vol.10, No.1，pp.90-103
Molecular Oncology，2015, Vol.9, No.4，pp.906-919

Also Published As

Publication number Publication date
AU2016347662A1 (en) 2018-05-10
IL258854B2 (en) 2025-06-01
KR20180102053A (ko) 2018-09-14
EP3368024B1 (en) 2023-09-20
IL258854B1 (en) 2025-02-01
CN109310648B (zh) 2022-06-03
CA3187317A1 (en) 2017-05-04
AU2016347662B2 (en) 2021-12-02
EP3368024A1 (en) 2018-09-05
US11090275B2 (en) 2021-08-17
CN109310648A (zh) 2019-02-05
WO2017072773A1 (en) 2017-05-04
BR112018008601A2 (pt) 2018-10-30
CA3002767C (en) 2023-03-14
US20180311182A1 (en) 2018-11-01
CA3002767A1 (en) 2017-05-04
IL258854A (en) 2018-06-28
JP2018536706A (ja) 2018-12-13

Similar Documents

Publication Publication Date Title
JP7078538B2 (ja) がんの治療のためのカンナビジオール及び第二の治療剤を含む組成物
US20220054429A1 (en) Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
Chen et al. Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways
Kang et al. Inhibition of EGFR signaling augments oridonin-induced apoptosis in human laryngeal cancer cells via enhancing oxidative stress coincident with activation of both the intrinsic and extrinsic apoptotic pathways
Zhang et al. Alpinetin inhibits breast cancer growth by ROS/NF‐κB/HIF‐1α axis
Sun et al. Juglanin induces apoptosis and autophagy in human breast cancer progression via ROS/JNK promotion
Martin et al. [10]-gingerol induces apoptosis and inhibits metastatic dissemination of triple negative breast cancer in vivo
Wu et al. Evodiamine ameliorates paclitaxel-induced neuropathic pain by inhibiting inflammation and maintaining mitochondrial anti-oxidant functions
Zhu et al. Erianin, a novel dibenzyl compound in Dendrobium extract, inhibits bladder cancer cell growth via the mitochondrial apoptosis and JNK pathways
Zhu et al. Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3
Pawlik et al. Sensitization of estrogen receptor-positive breast cancer cell lines to 4-hydroxytamoxifen by isothiocyanates present in cruciferous plants
CN101522609A (zh) 癌症的治疗
Park et al. Ameliorative effects of luteolin against endometriosis progression in vitro and in vivo
Shan et al. Fluoxetine protects against IL-1β-induced neuronal apoptosis via downregulation of p53
Si et al. Silibinin-induced mitochondria fission leads to mitophagy, which attenuates silibinin-induced apoptosis in MCF-7 and MDA-MB-231 cells
Dewangan et al. Chetomin induces apoptosis in human triple-negative breast cancer cells by promoting calcium overload and mitochondrial dysfunction
Jumnongprakhon et al. Protective effect of melatonin on methamphetamine-induced apoptosis in glioma cell line
JP2025119055A (ja) 癌治療
Minjie et al. Targeting pancreatic cancer cells by a novel hydroxamate-based histone deacetylase (HDAC) inhibitor ST-3595
CA2884784A1 (en) Combination of compounds derived from gallic acid for the treatment of cancer
Park et al. Particulate matter exposure induces adverse effects on endometrium and fertility via aberrant inflammatory and apoptotic pathways in vitro and in vivo
Huang et al. Quinolinic acid induces cell apoptosis in PC12 cells through HIF-1-dependent RTP801 activation
Emhemmed et al. The synthetic flavagline FL3 spares normal human skin cells from its cytotoxic effect via an activation of Bad
CN104662028B (zh) 对具有异常的脂肪生成信号的癌症进行治疗的组合物和方法
Chen et al. Sarsasapogenin protects hair cells from cisplatin-induced ototoxicity by attenuating apoptosis and ferroptosis via alleviating oxidative stress

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220406

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220419

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220519

R150 Certificate of patent or registration of utility model

Ref document number: 7078538

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250